AMENDMENTS TO THE CLAIMS

The following is a complete, marked up listing of revised claims with a status identifier in parentheses, underlined text indicating insertions, and strikethrough and/or double-bracketed text indicating deletions.

LISTING OF CLAIMS

1. (CURRENTLY AMENDED) A pharmaceutical compound comprising:

~~drug that comprises hollow nanoparticles of~~ a particle-forming protein ~~, that is~~ capable of recognizing a specific cell or tissue; and

~~, and is fused with~~ a disease-treating target-cell-substance fused to the particle-forming protein, wherein the protein forms a nanoparticle encapsulating the target-cell-substance.

2. (CURRENTLY AMENDED) The pharmaceutical compound according to~~drug as set forth in~~ claim 1, wherein:

the particle-forming protein comprises a hepatitis B virus surface-antigen protein.

3. (CANCELED)

4. (CURRENTLY AMENDED) The method for producing a pharmaceutical compound comprising according to ~~drug as set forth in~~ claim ~~3~~17, wherein:

the eukaryotic cell is selected from a group consisting of ~~a~~ yeast cells, insect cells, and

animal cells.

5. (CURRENTLY AMENDED) The method of treating a disease or a condition by administering a therapeutically effective amount of a pharmaceutical composition according to claim 18~~drug as set forth in~~ claim ~~1~~, wherein:

the disease or condition results from~~drug is used for treatment of~~ a hepatic diseases.

6. (CURRENTLY AMENDED) The pharmaceutical compound according to~~drug as set forth in~~ claim 1, wherein:

the target-cell substance is selected from a group consisting of ~~an~~ interferons, interleukins and ~~or a~~ hepatocyte growth factors.

7. (CURRENTLY AMENDED) The method of treating a disease or a condition by administering a therapeutically effective amount of a pharmaceutical composition according to claim 18~~drug as set forth in claims 1~~, wherein:

the ~~drug~~ pharmaceutical composition is administered using a method selected from a group consisting of ~~to the human body through~~ intravenous injection, oral administration, intramuscular administration, intraabdominal administration and subcutaneous administration.

8-16 (CANCELED)

17. (NEW) A method for producing a pharmaceutical compound comprising:

identifying a first gene that encodes for a particle-forming protein, the protein being configured to recognize a specific cell, tissue or receptor;

identifying a second gene that encodes for a target-cell peptide or a target-cell protein, the peptide or target-cell protein being configured to achieve a specific physiological effect;

synthesizing a vector including the first gene and, downstream of the first gene, the second gene;

transforming an eukaryotic cell with the vector to obtain a transformed eukaryotic cell; and

culturing the transformed eukaryotic cell and thereby expressing the first and second genes whereby the particle-forming protein is fused to and encapsulates the target-cell peptide or the target-cell protein and thereby forms the pharmaceutical compound.

18. (New) A method of treating a disease or a condition by administering a therapeutically effective amount of a pharmaceutical composition to a subject suffering from such a disease or condition wherein the pharmaceutical composition comprises:

a particle-forming protein configured to recognize a specific cell or tissue fused to a target-cell peptide or a target-cell protein configured to achieve a desired physiological effect and further wherein the particle-forming protein forms a nanoparticle encapsulating the target-cell peptide or the target-cell protein; and

a pharmaceutically acceptable excipient.

* * * * *